Arthritis Clinical Trials in Tampa

View 64 new treatments for Arthritis in Tampa, FL, and nearby areas, such as Clearwater, Lakeland and St. Petersburg. Every day, Power helps hundreds of arthritis patients connect with leading medical research.
View 55 trials in Tampa
Filter (55)

Upadacitinib vs Adalimumab for Rheumatoid Arthritis

AbbVie Clinic, Tampa + 8 more

This trial is testing two medications, upadacitinib (a daily pill) and adalimumab (an injection), for adults with rheumatoid arthritis who haven't responded to other treatments. The study aims to see which drug is safer and more effective. Both medications work by reducing inflammation through different mechanisms in the immune system. Adalimumab, an injection, has been extensively studied and used for treating rheumatoid arthritis, showing significant improvements in patients who have not responded to other treatments.Show More

Verified

Recruiting
Phase 3
Est. 5 - 8 Weeks
ABBVIE INC.
Study Director

QUC398 for Knee Osteoarthritis

Novartis Clinic, Tampa + 3 more

This trial is testing a new treatment called QUC398 to see if it can help people with knee osteoarthritis. The study will check if QUC398 can reduce knee pain and protect the cartilage in the knee. Researchers also want to make sure it is safe and well-tolerated.Show More

Verified

Recruiting
Phase 2
Est. 3 - 6 Weeks
Novartis Pharmaceuticals
Study Director

Baricitinib vs TNF Inhibitors for Rheumatoid Arthritis

Eli Lilly Clinic, New Port Richey + 3 more

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Guselkumab for Psoriatic Arthritis

Janssen Clinic, Tampa + 4 more

This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 5 - 8 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

COVID-19 Vaccines for Rheumatic Diseases

Research Clinic, Riverview + 1 more

Based on the experience with influenza, pneumococcal, and shingles vaccinations in rheumatic disease populations, it is clear that some disease modifying anti-rheumatic drugs and the immunomodulatory therapies used to treat immune-mediated inflammatory diseases have the capacity to blunt immune responses to COVID-19 vaccines. Several studies have suggested that patients with autoimmune conditions may be at increased risk of poor COVID-19 outcomes. There is an urgent need to better clarify the immunogenicity and safety of COVID-19 vaccines in people living with rheumatic disease who use immunomodulatory therapies. Boosters at annual or other frequency are available, and there is a need to understand whether these vaccines can be given concurrently with other routine vaccines.Show More
Waitlist

No Placebo Trial

Phase 4
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team

Baricitinib for Rheumatoid Arthritis

Eli Lilly Clinic, Saint Petersburg + 6 more

This trial compares the safety of two treatments for rheumatoid arthritis, focusing on the risk of blood clots. One treatment is baricitinib, an oral medication used for moderate to severe cases.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

TG-C for Knee Osteoarthritis

Kolon TissueGene Clinic, Clearwater + 1 more

This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
David W Romness, MD
Principal Investigator

Bimekizumab for Psoriatic Arthritis

UCB Biopharma Clinic, Tampa + 2 more

This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 6 Weeks
UCB Cares
Study Director

Tildrakizumab for Psoriatic Arthritis

Sun Clinic, New Port Richey + 2 more

This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Unregistered Study Lead
Research Team

Upadacitinib for Psoriatic Arthritis

AbbVie Clinic, Tampa + 9 more

The study objectives of Period 1 are to compare the efficacy, safety, and tolerability of upadacitinib 15 mg once daily (QD) and 30 mg QD versus placebo for the treatment of signs and symptoms in adults with moderately to severely active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to biologic disease-modifying anti-rheumatic drug (bDMARD). The objective of Period 2 is to evaluate the long-term safety, tolerability and efficacy of upadacitinib 15 mg QD and 30 mg QD in participants who have completed Period 1.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
AbbVie Inc.
Study Director
Page 1 of 6

Frequently Asked Questions

How much do arthritis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do arthritis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across arthritis trials in Tampa, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for arthritis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Tampa is research being conducted for arthritis?

Clinical trials for arthritis in Tampa are being conducted at Clinical Research of West Florida, with approximately 7 trials ongoing. Additionally, trials are taking place at Florida Orthopaedic Institute and ForCare Clinical Research, primarily in the northern areas of the city.

What promising new drugs are being tested?

In Tampa, arthritis research is focusing on treatments like Janus Kinase (JAK) Inhibitors and Monoclonal Antibodies. Notable drugs being studied include Upadacitinib, Risankizumab, and Guselkumab.